Overview
Employees
51-200
Founded date
1973
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 3, 2015 | Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour | There’s a reason sepsis still carries such a high mortality rate: For every hour that passes before proper treatment’s administered, a patient’s risk for death rises 7.6 percent. It’s a wildly expensive disease – cost more than $20 billion ... |
| Nov 11, 2013 | Janssen turns to Evotec for help discovering new targets and drugs for Alzheimer’s disease | If any products are commercialized from the collaboration, Evotec would receive royalty payments. But that’s a long way off — it would take years to identify targets and advance new drug candidates through preclinical and clinical developme... |
| Oct 17, 2012 | “Data is the new creative” sparks tiff and 5 more things you missed at a digital pharma conference | A tiff about data eclipsing creative marketing’s importance. A couple of the pharmaceutical trends highlighted in one presentation were about the increasing use of data to quantify consumer behavior, which also has a lot of implications for... |
| Jul 25, 2012 | With Care4Today, a spoonful of technology helps the medicine go down | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. Janssen Healthcare Innovation launched a mobile app today that helps people manage their medical needs. The app, Care4Today, keeps trac... |
| Mar 27, 2012 | Xarelto could set a new standard for treating pulmonary embolisms | Pulmonary embolisms are one of the most common causes of death in a hospital. For every 100,000 people there are 70 cases. Hospitalization is required and there’s a potential for recurrence. Xarelto, developed with Bayer, along with other a... |
| Mar 15, 2012 | Merck research center brings together scientists, entrepreneurs, VCs | Merck (NYSE:MRK) has launched a nonprofit translational research center in San Diego in a move that reflects the dizzy heights of the patent cliffs some Big Pharma companies are facing. The Whitehouse Station, New Jersey company is providin... |
| Mar 5, 2012 | GSK adds vaccine candidate to AGEN pact, gets first right to buy the firm | If GSK can commercialize a vaccine in the added undisclosed indication, Agenus will gain additional royalties on that product. In addition to the added vaccine indication, Britain-based GSK gets the first right to negotiate for the purchase... |
| GSK adds vaccine candidate to AGEN pact, gets first right to buy the firm | GlaxoSmithKline (NYSE:GSK) is adding another vaccine target to its partnership with Agenus (NASDAQ:AGEN) and putting itself first in line to acquire the vaccines company outright. GSK is paying Massachusetts-based Agenus $9 million to amend... | |
| “Data is the new creative” sparks tiff and 5 more things you missed at a digital pharma conference | One of the most notable things about the digital pharmaceutical sector is that it’s accepted and is now a valid part of pharmaceutical marketing. The impact of having so many tools to track consumer and physician behavior online, and to see... |
Show more